Zealand Pharma Announces Positive Phase 2 Results for Petrelintide in Obesity, Advancing to Phase 3 Trials

Zealand Pharma has announced positive Phase 2 results for its obesity asset, petrelintide, demonstrating double-digit weight loss with a tolerability profile comparable to placebo. Following these promising results, the company plans to advance petrelintide into Phase 3 trials in the second half of 2026, aiming to offer a differentiated treatment option for individuals living with obesity or overweight.